Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL
Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.
Javier Pinilla Exploring Therapeutic Advancements Chronic Lymphocytic Leukemia Treatment Resistance Therapy Strategies Off Target Aes
Source: onclive.com